• Company
    • About
    • Leadership
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • Immuno-Oncology
      • BND-22
      • BND-35
      • BION-206
    • INspire Technology
  • News
    • Public Relations
    • Events
  • Collaborations
  • Contact Us
  • Company
    • About
    • Leadership
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • Immuno-Oncology
      • BND-22
      • BND-35
      • BION-206
    • INspire Technology
  • News
    • Public Relations
    • Events
  • Collaborations
  • Contact Us

Public Relations

Biond Biologics Announces Global Licensing Agreement with Sanofi for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

January 12, 2021

Biond Biologics Announces Global Licensing Agreement with Sanofi for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

January 12, 2021

Biond Biologics Announces Poster Presentations at AACR 2020 Virtual Annual Meeting

June 9, 2020

Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update

June 1, 2020

Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory Board

November 25, 2019

Biond Biologics Annual Company Gathering | Misgav Industrial Park

May 12, 2019

Biond Biologics Announces $17 Million Financing

January 8, 2019

© Copyright 2020

Designed by YuvalDesign